MCL1 and lung cancer: RT, TM-(–)-18, and TM-(–)-4a were the active compounds that were demonstrated to have potent anti-cancer activity in lung cancer cells, and information on the SARs of these compounds could encourage the development of related compounds having these groups for Mcl-1 suppression.